Differentiation of atazanavir from other HIV-protease inhibitors in preclinical models of glucose uptake, lipogenesis and proteasome function

被引：0

|

作者：

Wang, S ^{[1
]}

Mulvey, R ^{[1
]}

Laing, N ^{[1
]}

Leet, J ^{[1
]}

Flint, O ^{[1
]}

Parker, RA ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA

来源：

ANTIVIRAL THERAPY | 2002年 / 7卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

10

引用

收藏

页码：L6 / L7

页数：2

相关论文

共 3 条

[1] Transcriptional profiles support proteasome modulation hypothesis for lipid disturbances of current HIV-protease inhibitors and lipid neutrality of atazanavir
Parker, RA
Yang, WP
Wang, S
Fenderson, W
Mulvey, R
Laing, N
Flint, OP
ANTIVIRAL THERAPY, 2003, 8 (04) : L49 - L49
[2] Comparative effects of atazanavir versus other HIV protease inhibitors on glucose and amino acid stimulated insulin secretion
Flint, OP
Lubinski, J
Parker, RA
Noor, MA
ANTIVIRAL THERAPY, 2005, 10 (08) : L32 - L32
[3] HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART
Lucia, MB
Rutella, S
Leone, G
Vella, S
Cauda, R
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 27 (04) : 321 - 330